- Dominican Republic to vote in poll dominated by Haiti crisis
- The Dominican Republic: from Columbus to cruise ships
- Forced to give birth after rape, Honduran woman seeks UN remedy
- Reddit gives OpenAI access to its wealth of posts
- Turkey court jails Kurdish leader for 42 years over 2014 unrest
- US plans to end leasing in its largest coal-producing region
- Kim's sister denies N. Korea exporting weapons to Russia
- Schauffele equals record-low major round with 62 to lead PGA
- Alternate Lee seizes opportunity to grab LPGA Americas Open lead
- Swiatek to face Sabalenka for Rome title and Serena record
- Mystik Dan goes for Triple Crown 2nd leg in Preakness
- 'Grand Theft Auto VI' release set for late 2025
- Global coral bleaching event expanding to new countries: scientists
- US Republicans confront Biden over pausing arms to Israel
- Lopez double earns Barca win at relegated Almeria
- Weather eases Canadian oil sands city wildfire menace
- Messi's record $20.4 million salary dwarfs entire MLS teams
- Jarry stuns Tsitsipas to reach Rome Open semi-finals
- US ends leasing in its largest coal-producing region
- Chad junta chief officially wins election
- Florida slammed for bill striking climate change from state law
- Exhibition traces Jewish origins of Hollywood
- 'I'm ready': Fury to pray for Usyk before heavyweight clash
- Murray's French Open build-up suffers Bordeaux glitch
- Ethiopian legend Bekele returns to Olympics after 12 years
- McIlroy passes emotional test to stay in hunt for PGA win
- Coppola's long-awaited epic 'Megalopolis' divides Cannes
- Ukraine battles to hold back Russia advance
- Kante returns from wilderness as Deschamps announces France Euro squad
- Superb Schauffele plays his best with hunger to end win drought
- Paraguay leader to attend Taiwan inauguration
- Military rank affects medical care, offering societal insights: study
- US proposes reclassifying marijuana as low-risk drug
- Cannes film shocks with fairy-tale horror on abortion
- Schauffele equals major record low round with 62 to lead PGA
- Schauffele ties record-low major round with 62 for PGA lead
- Slovak PM speaking but serious after shooting, suspected gunman charged
- Ten Hag warns England's Shaw doubtful for Euro 2024
- Swiatek into Rome Open final as trophy record beckons, Paul battles through
- US bank regulator grilled over 'toxic culture' at agency
- Nigeria lawmaker's plan for mass wedding of orphans sparks uproar
- Ukraine trying to 'stabilise' front as Russia pushes northeast
- 'Fighter' Alaphilippe back winning in Giro 12th stage, Pogacar holds lead
- Demirtas: Erdogan's Kurdish nemesis condemned to prison
- Juve's Allegri suspended two matches after cup final red
- Hamilton says struggling Mercedes have found 'North Star'
- Trump lawyers vie to discredit key witness Cohen at trial
- England centre Slade signs new Exeter deal to end talk of France move
- Brazil's Porto Alegre: a flood disaster waiting to happen
- Resilient Schauffele grabs PGA lead as McIlroy's emotions tested
Weight-loss drug maker Novo Nordisk's profits soar further
Danish pharmaceutical giant Novo Nordisk reported more soaring profits on Thursday thanks to the popularity of anti-diabetes and weight-loss drugs Ozempic and Wegovy, which have made it Europe's most valuable company.
Its net profit reached 25.4 billion kroner ($3.6 billion) in the first quarter, a 28 percent jump from the same period last year, the company said in a statement.
Sales rose by 24 percent at current exchange rates to 65.3 billion kroner -- almost two billion kroner higher than forecast by analysts surveyed by Bloomberg and financial data firm FactSet.
Novo Nordisk raised its outlook for 2024, saying it now expects sales to rise by between 19 to 27 percent -- up from 18-26 percent previously.
"More patients benefit from our innovative treatments," Novo Nordisk chief executive Lars Fruergaard Jorgensen said in a statement.
The drugmaker increased its market share of the diabetic treatment market by 1.8 percentage points and now has a 34-percent share of the market.
Novo Nordisk saw its biggest growth in North America, with the United States accounting for 76 percent of the increase in sales.
Novo Nordisk produces Ozempic, an injectable anti-diabetic treatment which has become popular on social networks for its reported slimming properties.
It also makes Wegovy, which has the same active ingredient as Ozempic in a different dose and was approved by US regulators to treat obesity.
The treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
- Ramping up production -
Sales of Wegovy soared by 106 percent in the first quarter compared to a year earlier and those of Ozempic by 42 percent.
The rise in demand has led to supply constraints, and to step up production for its blockbuster drugs, Novo Nordisk is acquiring US drug manufacturing firm Catalent.
"The agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future," Fruergaard Jorgensen added.
A global health scourge, obesity is a risk factor for cardiovascular disease, diabetes, certain cancers and complications from diseases such as Covid-19.
Difficult to treat, it is costly for healthcare systems and while its causes can be lifestyle-related, it can also be influenced by genetics.
The World Obesity Federation predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.
Novo Nordisk also develops treatments for rare diseases such as haemophilia and makes growth hormones but sales of these fell by three percent in the first quarter due to supply constraints.
The Danish giant employs more than 64,000 people in 80 countries.
A.Gasser--BTB